- Home
- RIBB vs ACET Comparison
RIBB vs ACET Comparison
Compare RIBB & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIBB
- ACET
- Stock Information
- Founded
- RIBB 2024
- ACET 1947
- Country
- RIBB Japan
- ACET United States
- Employees
- RIBB N/A
- ACET N/A
- Industry
- RIBB
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- RIBB
- ACET Health Care
- Exchange
- RIBB NYSE
- ACET Nasdaq
- Market Cap
- RIBB 64.9M
- ACET 55.1M
- IPO Year
- RIBB 2025
- ACET N/A
- Fundamental
- Price
- RIBB $10.08
- ACET $0.72
- Analyst Decision
- RIBB
- ACET Buy
- Analyst Count
- RIBB 0
- ACET 6
- Target Price
- RIBB N/A
- ACET $6.00
- AVG Volume (30 Days)
- RIBB 215.0
- ACET 764.4K
- Earning Date
- RIBB 01-01-0001
- ACET 05-06-2025
- Dividend Yield
- RIBB N/A
- ACET N/A
- EPS Growth
- RIBB N/A
- ACET N/A
- EPS
- RIBB N/A
- ACET N/A
- Revenue
- RIBB N/A
- ACET N/A
- Revenue This Year
- RIBB N/A
- ACET N/A
- Revenue Next Year
- RIBB N/A
- ACET N/A
- P/E Ratio
- RIBB N/A
- ACET N/A
- Revenue Growth
- RIBB N/A
- ACET N/A
- 52 Week Low
- RIBB $9.95
- ACET $0.45
- 52 Week High
- RIBB $10.45
- ACET $1.70
- Technical
- Relative Strength Index (RSI)
- RIBB N/A
- ACET 53.94
- Support Level
- RIBB N/A
- ACET $0.64
- Resistance Level
- RIBB N/A
- ACET $0.72
- Average True Range (ATR)
- RIBB 0.00
- ACET 0.06
- MACD
- RIBB 0.00
- ACET 0.01
- Stochastic Oscillator
- RIBB 0.00
- ACET 60.07
About RIBB RIBBON ACQUISITION CORP
Ribbon Acquisition Corp is a blank check company.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.